Global Artificial Insemination Market Research Report—Forecast till 2027

$4,450$6,250

Global Artificial Insemination Market was valued at USD 1,818.29 Million in 2019 and is expected to register a CAGR of 8.6% during the forecast period of 2020 to 2027. An expanding number of medical insurance agencies offering inclusion for couples of equivalent genders is probably expected to attain the growth for the global artificial insemination market to develop.

Clear

Description

Global Artificial Insemination Market Research Report—Forecast till 2027

Market Overview
Global Artificial Insemination Market was valued at USD 1,818.29 Million in 2019 and is expected to register a CAGR of 8.6% during the forecast period of 2020 to 2027. An expanding number of medical insurance agencies offering inclusion for couples of equivalent genders is probably expected to attain the growth for the global artificial insemination market to develop. The rising mindfulness about barrenness and the potential medicines like artificial insemination, IVF, and other novel methods increment the fruitfulness rate for different nations. The government support through repayment and co-pay system is expected to raise the number of manufacturers entering the market in developing countries.

The global artificial insemination market is expected to register significant market growth during the review period. The global market growth is driven by the rising infertility rate in the world and changing lifestyles. Moreover, the developing regulatory scenarios related to artificial insemination and technological developments in artificial insemination are expected to drive the global market during the review period. Additionally, the rising fertility-related disorders are one of the prime factors contributing to the growth of artificial insemination.
Market Segmentation
Global Artificial Insemination Market has been divided based on Type and End User.
Based on type segment, the global artificial insemination market has been divided into intrauterine, intracervical, and intratubal. The increasing prevalence of infertility and technological advancements in artificial insemination are driving the growth of the market. As per the World Health Organization, around 48 million couples were living with infertility globally as of September 2020.
Based on the end-user segment, the global artificial insemination market has been classified as hospitals & clinics, fertility centers, and home-based. The hospitals & clinics segment dominated the global artificial insemination market in 2019. Its large share of 49.0% is attributable to a rising preference for insemination procedures in clinics.
Regional Analysis
Geographically, Global Artificial Insemination Market has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to lead the global artificial insemination market owing to the largest market share of 40.8% in 2019. The regional market is attributed to the large number of companies operating in the region. Additionally, the government regulations and healthcare expenditure by the countries in the region are fuelling the market growth during the review period. Europe held a prominent share in the global artificial insemination market followed by the Asia Pacific during the review period.

Major Players
The Key Players in the Global Artificial Insemination Market are Vitrolife AB, Genea Limited, Rinovum Women’s Health, LLC, Pride Angel, Hi-tech Solutions, Kitazato Corporation, Fujifilm Irvine Scientific, and Rocket Medical.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENT
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 14

2.2 RESEARCH OBJECTIVE 14

2.3 MARKET STRUCTURE 14

2.4 ASSUMPTIONS & LIMITATIONS 15

3 RESEARCH METHODOLOGY
3.1 DATA MINING 16

3.2 SECONDARY RESEARCH 17

3.3 PRIMARY RESEARCH 18

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19

3.5 FORECASTING TECHNIQUES 19

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 20

3.6.1 BOTTOM-UP APPROACH 21

3.6.2 TOP-DOWN APPROACH 21

3.7 DATA TRIANGULATION 22

3.8 VALIDATION 22

4 MARKET DYNAMICS
4.1 OVERVIEW 23

4.2 DRIVERS 24

4.2.1 GROWING RATE OF INFERTILITY IN THE WORLD 24

4.2.2 CHANGING LIFESTYLE AMONG POPULATION 24

4.2.3 RISE IN NHS FUNDED IN FERTILITY MARKET 24

4.3 RESTRAINTS 25

4.3.1 HIGH RISK OF CONCEIVING TWINS OR TRIPLETS AND OTHER COMPLICATIONS SUCH AS PREMATURE BIRTH OR MISCARRIAGE 25

4.4 OPPORTUNITIES 26

4.4.1 MEDICAL INSURANCE FOR THE COUPLES OF SAME SEXES 26

5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 27

5.1.1 CONSULTING DOCTOR FOR EVALUATION 27

5.1.2 FERTILITY TESTING OF MALE & FEMALE 28

5.1.3 DIAGNOSIS 28

5.1.4 INSEMNINATION OF SPERM 28

5.2 PORTER’S FIVE FORCES MODEL 29

5.2.1 BARGAINING POWER OF SUPPLIERS 29

5.2.2 BARGAINING POWER OF BUYERS 29

5.2.3 THREAT OF NEW ENTRANTS 29

5.2.4 THREAT OF SUBSTITUTES 30

5.2.5 RIVALRY 30

5.3 COVID-19 IMPACT ANALYSIS 30

5.3.1 IMPACT ON GROWTH RATE 30

5.3.2 IMPACT ON MAJOR PLAYERS 30

5.3.3 IMPACT ON MAJOR REGIONS 30

6 GLOBAL ARTIFICIAL INSEMINATION MARKET, BY TYPE
6.1 OVERVIEW 32

6.2 INTRAUTERINE 33

6.3 INTRACERVICAL 33

6.4 INTRATUBAL 34

7 GLOBAL ARTIFICIAL INSEMINATION MARKET, BY END USER
7.1 OVERVIEW 35

7.2 HOSPITALS & CLINICS 36

7.3 FERTILITY CENTRE 36

7.4 HOME-BASED 37

8 GLOBAL ARTIFICIAL INSEMINATION MARKET, BY REGION
8.1 OVERVIEW 38

8.2 AMERICAS 39

8.2.1 NORTH AMERICA 40

8.2.1.1 US 41

8.2.1.2 CANADA 42

8.2.2 LATIN AMERICA 43

8.3 EUROPE 44

8.3.1 WESTERN EUROPE 45

8.3.1.1 GERMANY 47

8.3.1.2 FRANCE 47

8.3.1.3 UK 48

8.3.1.4 ITALY 49

8.3.1.5 SPAIN 49

8.3.1.6 BELGIUM 50

8.3.1.7 SWEDEN 51

8.3.1.8 DENMARK 51

8.3.1.9 FINLAND 52

8.3.1.10 NORWAY 53

8.3.1.11 REST OF WESTERN EUROPE 53

8.3.2 EASTERN EUROPE 54

8.4 ASIA-PACIFIC 55

8.4.1 JAPAN 56

8.4.2 CHINA 57

8.4.3 INDIA 58

8.4.4 AUSTRALIA 58

8.4.5 SOUTH KOREA 59

8.4.6 REST OF ASIA-PACIFIC 60

8.5 MIDDLE EAST & AFRICA 61

8.5.1 MIDDLE EAST 62

8.5.2 AFRICA 63

9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW 64

9.2 COMPETITIVE BENCHMARKING 65

9.3 COMPETITOR DASHBOARD 66

9.4 MAJOR GROWTH STRATEGY IN THE GLOBAL ARTIFICIAL INSEMINATION MARKET 67

9.5 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL ARTIFICIAL INSEMINATION MARKET 67

9.6 KEY DEVELOPMENT ANALYSIS 68

9.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 68

9.7.1 PARTNERSHIPS/COLLABORATIONS/AGREEMENTS 68

9.7.2 EXPANSIONS 68

10 COMPANY PROFILES
10.1 VITROLIFE AB 69

10.1.1 COMPANY OVERVIEW 69

10.1.2 FINANCIAL OVERVIEW 70

10.1.3 PRODUCTS/SERVICES OFFERED 71

10.1.4 KEY DEVELOPMENTS 71

10.1.5 SWOT ANALYSIS 72

10.1.6 KEY STRATEGIES 72

10.2 GENEA LIMITED 73

10.2.1 COMPANY OVERVIEW 73

10.2.2 FINANCIAL OVERVIEW 73

10.2.3 PRODUCTS/SERVICES OFFERED 73

10.2.4 KEY DEVELOPMENTS 73

10.2.5 SWOT ANALYSIS 74

10.2.6 KEY STRATEGIES 74

10.3 RINOVUM WOMEN’S HEALTH, LLC 75

10.3.1 COMPANY OVERVIEW 75

10.3.2 FINANCIAL OVERVIEW 75

10.3.3 PRODUCTS/SERVICES OFFERED 75

10.3.4 KEY DEVELOPMENTS 75

10.3.5 SWOT ANALYSIS 76

10.3.6 KEY STRATEGIES 76

10.4 PRIDE ANGEL 77

10.4.1 COMPANY OVERVIEW 77

10.4.2 FINANCIAL OVERVIEW 77

10.4.3 PRODUCTS/SERVICES OFFERED 77

10.4.4 KEY DEVELOPMENTS 77

10.4.5 SWOT ANALYSIS 78

10.4.6 KEY STRATEGIES 78

10.5 HI-TECH SOLUTIONS 79

10.5.1 COMPANY OVERVIEW 79

10.5.2 FINANCIAL OVERVIEW 79

10.5.3 PRODUCTS/SERVICES OFFERED 79

10.5.4 KEY DEVELOPMENTS 79

10.5.5 SWOT ANALYSIS 80

10.5.6 KEY STRATEGIES 80

10.6 KITAZATO CORPORATION 81

10.6.1 COMPANY OVERVIEW 81

10.6.2 FINANCIAL OVERVIEW 81

10.6.3 PRODUCTS/SERVICES OFFERED 81

10.6.4 KEY DEVELOPMENTS 82

10.6.5 SWOT ANALYSIS 82

10.6.6 KEY STRATEGIES 82

10.7 FUJIFILM IRVINE SCIENTIFIC, INC. 83

10.7.1 COMPANY OVERVIEW 83

10.7.2 FINANCIAL OVERVIEW 83

10.7.3 PRODUCTS/SERVICES OFFERED 84

10.7.4 KEY DEVELOPMENTS 84

10.7.5 SWOT ANALYSIS 84

10.7.6 KEY STRATEGIES 85

10.8 ROCKET MEDICAL 86

10.8.1 COMPANY OVERVIEW 86

10.8.2 FINANCIAL OVERVIEW 86

10.8.3 PRODUCTS/SERVICES OFFERED 87

10.8.4 KEY DEVELOPMENTS 87

10.8.5 SWOT ANALYSIS 87

10.8.6 KEY STRATEGIES 87

11 APPENDIX
11.1 REFERENCES 88

11.2 RELATED REPORTS 89

RSS
Follow by Email